{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-000424","form_type":"8-K/A","ticker":"HRMY","cik":"0001802665","company_name":"Harmony Biosciences Holdings, Inc.","filed_at":"2023-01-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.635461+00:00","generated_at":"2026-06-20T11:56:06.422916+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Harmony Biosciences appoints Dayno as Interim President and CEO; details compensation","bullets":["Dr. Jeffrey Dayno appointed Interim President and CEO effective Jan 6, 2023; continues as CMO.","Annual base salary set at $530,000; target annual bonus of 75% of base salary.","One-time cash bonus of $300,000 payable upon earlier of June 30, 2024 or change in control.","Upon permanent CEO appointment, Dayno reverts to EVP/CMO with base salary $530,000 and 75% target bonus.","Executive Chairman Jeffrey Aronin to receive $500,000 annual cash payment, pro-rated quarterly."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-000424","json":"https://secwatch.observer/filing/0001558370-23-000424.json","markdown":"https://secwatch.observer/filing/0001558370-23-000424.md","text":"https://secwatch.observer/filing/0001558370-23-000424.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/hrmy-20230105x8ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T11:56:06.422916+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9717b0cbaf","claim":"Jeffrey S. Aronin was appointed as Executive Chairman at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"the Board appointed Jeffrey S. Aronin, currently Chairman of the Board, as the Company’s Executive Chairman, effective January 6, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"c3ff762467","claim":"John Jacobs resigned as other at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"in connection with Mr. John Jacobs’ resignation from the Company and the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm","confidence":0.7,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"}],"fact_type":"executive_change"},{"claim_id":"f9febc0035","claim":"Jeffrey M. Dayno was appointed as Interim President and Chief Executive Officer at Harmony Biosciences Holdings, Inc..","evidence_excerpt":"the Board appointed Dr. Jeffrey M. Dayno as the Company’s Interim President and Chief Executive Officer (“CEO”), effective January 6, 2023.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1802665/000155837023000424/0001558370-23-000424-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Interim President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}